

## PEOPLE

Ligand Pharmaceuticals (San Diego, CA) has appointed Russell L. Allen to the newly created position of vice president, corporate development and strategic planning. Most recently he was a general manager at Sanofi Winthrop.

Gliatech Inc. (Cleveland, OH) has announced that it has promoted Kurt Brunden to vice president, research. Dr. Brunden joined Gliatech in 1991 as head of biomolecular and chemical research, and was instrumental in developing and directing its research program to discover and develop drug candidates for the treatment of Alzheimer's disease.

IntroGene BV (Rijswijk, The Netherlands), a gene therapy company, has announced the appointment of Ronald Brus to the position of vice president, business development. Dr. Brus joins IntroGene from Forest Laboratories in the US, where he had been director of product planning since 1994.

BioTransplant Inc. (Charlestown, MA) has announced that Donald R. Conklin has joined the company's board of directors. Mr. Conklin has recently retired from his positions as chairman of Schering-Plough HealthCare Products and executive vice president of Schering-Plough Corp.

LXR Biotechnology (Richmond, CA) has appointed Jerilyn G. Domagala as director of regulatory affairs and John Statler as director of analytical chemistry, quality assurance/quality control. Previously, Ms. Domagala was director of regulatory affairs at Cytel Corp., and Dr. Statler was manager of appli-

cations at Dionex Corp.



Larry Ellingsworth has been named executive vice president and chief scientific officer of Meta-Morphix (Baltimore, MD). Previously, Dr. Ellingsworth was CEO and CSO of Cystar, Inc. He has also held vice president positions in research and operations at Celtrix Pharmaceuticals.

John H. Fried has been named chairman of the board of directors of Corvas International (San Diego, CA). Dr. Fried has been a director of, and consultant to, Corvas since 1992, and also serves as the chairman of the board of Alexion Pharmaceuticals and president of his own consulting firm. He replaces David S. Kabakoff, who has been chairman since January 1996.



The National Center for Genome Resources (Santa Fe, NM), a not-for-profit organization established in 1994 to facilitate broader use of information generated by various genome projects within the public and private sectors, has appointed Steven D. Goldby to its board of directors. Mr. Goldby is chairman and CEO of MDL Information Systems.

Leland Hartwell has been named president and director of the Fred Hutchinson Cancer



Research Center (Seattle, WA) after a year-long search for a successor to Robert Day, who will retire effective June 30, 1997 after serving as president and director for 16 years. Dr. Hartwell has been the center's scientific advisor since April 1996.

David A. Kessler, commissioner of the US Food and Drug Administration, will become dean of the Yale University School of Medicine (New Haven, CT), effective July 1, 1997. Dr. Kessler has served as FDA commissioner since 1990. He succeeds Gerard N. Burrow, who will be returning to the faculty and will serve as special adviser for health affairs to university president Richard C. Levin.

Human Genome Sciences (Rockville, MD) has announced that Arthur M. Mandell will join the company as senior vice president, business development. He will succeed the retiring Bradley G. Lorimier. Mr. Mandell served in senior management positions at Syntex until 1995, when he became a principal of ZS Associates, a consulting firm.


Structural Bioinformatics (San Diego, CA) has announced that Arthur J. Olson, professor of molecular biology and director of the molecular graphics laboratory at The Scripps Research Institute, and Douglas Smith, professor of biology at the University of California, San Diego, have joined its scientific advisory board.

## Solid Phase Synthesizers

SOPHAS represents a new generation of automatic Solid Phase Synthesizers for up to 864 synthesis in a single run. It is an automatic chemical workbench, which gives maximum freedom in the choice of the reactors (from a 96-well plate to 25 ml reaction vessels).

It provides heating (up to 150° C), cooling (to 80° C) and mechanical agitation at any stage of the synthesis. The system uses 4 independent pipetting probes, each supported by 2 dilutors and a time/pressure delivery channel to deliver 4-5 system reagents (solvents), nitrogen and/or argon. Solids and non-conductive solvents can now be detected using the newly developed level sensor. Electrodes and sensors can be picked up by the probes to monitor the chemical reactions.

The software is based on Windows NT. There is no limitation in the choice of chemistry.



The software can import data from any database. Information can be received from ZINSSER ANALYTIC GmbH, Eschborner Landstraße 135, D-60489 Frankfurt/Germany, Phone (069)789106-0, Telefax (069)789106-80

READER INQUIRY NO. 211